PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcdrAbout UsAuthor ServicesArchiveSubmitJCDR
 
J Clin Diagn Res. 2017 June; 11(6): ZE01–ZE06.
Published online 2017 June 1. doi:  10.7860/JCDR/2017/25920.9967
PMCID: PMC5535495

Familial Cancers of Head and Neck Region

Abstract

Cancers that occur in families more often than would be expected by chance are termed as familial cancers. They occur due to an inherited genetic mutation and account for 5%-10% of all cancers. This review article presents some of the common Familial Cancer Syndromes (FCS) such as MEN 2B, hyperparathyroidism-jaw tumour syndrome, familial oral squamous cell carcinoma, melanoma, nasopharyngeal carcinoma, paraganglioma, neurofibroma and other syndromes associated with head and neck region.

Keywords: Germline mutation, Genetic susceptibility, Multiple abnormalities, Oral manifestations

Introduction

Cancer that occurs in families more often than would be expected by chance is termed as familial cancers [1]. These rare cancers often occur at an early age. FCS increase the risk of cancers and are associated with various physical symptoms. They may also be a sign of shared environmental or lifestyle factors that resulted in inherited genetic mutation [2,3].

The following clues provided by Neel and Schull (1954) categorize a tumour to be of genetic origin:

  1. The occurrence of the disease in defined proportions among persons related by descent, when environmental causes can be ruled out.
  2. The failure of the disease to appear in unrelated lines (e.g., in spouses or in-laws)
  3. A characteristic age of onset and course, in the absence of known precipitating factors.
  4. Greater concordance in monozygotic than in dizygotic twins [4].

A clinician should be cautious and suspect a FCS when two or more members of the same side of a family present with similar kind of cancer, an earlier age of onset, has birth defects, when a person has more than one primary cancer, family member with cancer clusters belonging to known FCS and with an evidence of inherited gene mutation [5].

The inheritance pattern seen in familial cancer syndromes is presented in [Table/Fig-1] [2,6].

[Table/Fig-1]:
Inheritance pattern in familial syndromes.

The primary genetic event either a germline mutation in a tumour suppressor or an oncogene has been identified in approximately 19 FCS. Patients predisposed to FCS inherit one mutant allele of genes (either maternal or paternal) and neoplasia develops only when additional mutation of remaining allele occurs. For instance, in syndromes of tumour suppressor or caretaker genes, patients inherit a single mutant allele of a caretaker gene from an affected parent and only develop cancer after three further somatic mutations (the remaining allele of the caretaker gene and both alleles of a gatekeeper gene). In contrast, sporadic tumours develop in individuals who do not have a germline mutation but who acquire, over a period of time, somatic mutations of both alleles. In general, germline mutations are scattered largely along the entirety of the gene [1,2,7].

Familial cancers often involve multiple organ systems and affect paired organs with bilateral or multifocal tumours. Affected individuals can have more than one type of cancer and malignancies other than epithelial are more likely to occur (soft tissue sarcomas, leukaemias/ lymphomas, nervous system tumours) [8].

A search was conducted with keywords “familial tumours”, “familial cancer syndromes” and “familial tumours in head and neck” in Pubmed, Pubmed Central, Science Direct, Wiley Interscience, Google, Google Scholar to identify the FCS associated with head and neck region. Cancers with predominant oral origin and manifestations were mainly considered.

The familial cancers thus identified are listed in [Table/Fig-2] [2,3,9-14]:

[Table/Fig-2]:
Familial cancers with oral manifestations.

Multiple Endocrine Neoplasia Syndrome

Multiple Endocrine Neoplasia (MEN) syndrome, an autosomal dominant disorder is characterized by simultaneous occurrence of tumours involving two or more endocrine glands derived from neural crest. They develop tumours involving parathyroid gland, pancreas, pituitary gland, adrenal gland and thyroid gland [15].

The major forms of MEN are MEN 1 or Wermer’s syndrome with menin (protein product of MEN 1 gene) mutations, MEN2/MEN2A/ Sipple’s syndrome with mutations in Rearranged During Transfection (RET) protoncogene a transmembrane tyrosine kinase receptor, MEN3/ MEN2B/ Wagenmann-Froboese/mucosal neuroma syndrome with RET mutations located on 10q11.2 and MEN4/MEN X with cyclin-dependent kinase inhibitor (CDNKI) B mutations [15,16].

The oral manifestations are most prominent in MEN 2B and hence the manifestations of this syndrome are discussed [17-19].

The incidence rate is 1 in 30,000. Approximately 95% of the MEN 2B patients carry M918T (exon 16) missense mutation, whereas others harbor a mutation at codon 883 and 918 (exon 15) in the tyrosine kinase domain. These mutations interfere with ATP binding, altering the substrate specificity of RET substrate recognition pocket which leads to ligand-independent activation or modification of kinase activity [16].

Pathological mucosal nerve proliferations associated with increase in size and number of nerve fascicle with thickened perineurium is seen. No intradermal axon flare response to histamine is noticed. Intraosseous neural hyperplasia is a specific finding of the MEN 2B syndrome. The oral mucosal lesions are more commonly neurofibromas (plexiform type) than neuromas [17-19].

Around 25% of medually thyroid carcinoma are hereditary, associated with MEN 2 syndrome and present with early aggressive behaviour. They are bilateral and metastasize early [15].

Familial Hyperparathyroidism with Jaw Tumour Syndrome

Primary hyperparathyroidism results from persistent hypercalcaemia with inadequate secretion of parathyroid hormone. About 5%-10% of cases are inherited (autosomal dominant trait) as a part of syndromes such as multiple endocrine neoplasia, Hyperparathyroidism Jaw-Tumour (HPT-JT), Neonatal Severe Hyperparathyroidism (NSHPT), Familial Hypocalciuric Hypercalcaemia (FHH), Familial Isolated Hyperparathyroidism (FIHPT) and Autosomal Dominant Moderate Hyperparathyroidism (ADMH) and most other cases are sporadic [9,20].

Familial types are more heterogenous, presents with multiglandular parathyroid disease (conventionally parathyroid hyperplasia) and occur with equal frequencies in both sexes [9,20].

HPT-JT presents with oral manifestations and around 300 cases from approximately 100 families (world-wide) have been described till date. Virtually all patients with HPT-JT develop primary hyperparathyroidism and average age of onset is 32 years [9,20,21].

Inactivating mutations of cell division cycle 73 (CDC73)/hyperparathyroidism 2 (HRPT2) gene (1q31.2) that encodes parafibromin, a tumour suppressor protein in parathyroid gland is noticed. It interacts with Polymerase Associated Factor 1 (PAF1) to regulate histone ubiquitination, apoptosis, gene transcription, growth factor gene transcription, cyclin D1 signalling and Wnt/b-catenin signalling. Bi-allelic inactivation of CDC73/HRPT2 and complete loss of parafibromin expression results in parathyroid cancer [9].

Severe hypercalcaemia (albumin corrected calcium >3 mmol/l), a large palpable neck mass of size more than 3 cm, third/second generation PTH assay ratio >1, infiltrative parathyroid gland disease or suspected metastasis on sestamibi scintigraphy are all the features of parathyroid cancer [9].

In patients aged less than 35 years with hyperparathyroidism, parathyroid cancer/cystic change, loss of parafibromin staining or family history of HPT-JT syndrome; genetic analysis for HPT-JT should be performed [9,20,21].

Familial Oral Squamous Cell Carcinoma

Oral squamous cell carcinoma is a malignant epithelial tumour with squamous differentiation characterized by the formation of keratin or the presence of intercellular bridges or both [22].

Familial OSCC occurs as an autosomal dominant disorder and the estimated risks of first degree relatives have been reported to be 1.1, 9.25, 103.5 or 3.812 by various studies. The homozygous genotype may increase the risk/odds ratio to 1.77. It can be acquired as a genetic trait in families with high-risk habits such as smoking and alcohol use [22,23]. Evidence for hereditary syndrome associated OSCC includes occurrence of tumours in family groups having different lifestyles, early onset in non-smokers or individuals lacking any risk factors, and/or aggregation in families by tumour site. Development of second primary tumours is the main cause of treatment failure [23].

The following criteria was selected in one of the study for familial OSCCs: 1) minimum of two first-degree relatives affected with head and neck cancer and/or other related cancers (cancer of stomach, kidney, breast, uterus, cervix etc.,); 2) less than 45 years of age of onset in at least one of the affected family members; 3) OSCC patient with no known aetiological factors such as tobacco or alcohol use, at any age of onset [24].

Mutation of various genes is observed, such as germ line p53 alterations with first degree relatives affected by multiple malignancies, missense mutations located primarily in exons 4+/- 9 with hot spot codons 205+/-248 associated with Li Fraumeni syndrome and impairment in regulator proteins such as overexpression of MDM2. Overexpression of MDM2 is associated with 52% increase in premalignant lesions and 78% increase in OSCC in Indians [7]. The CDKN 2 locus is frequently deleted; a protein encoded by the ADP-Ribosylation Factor 1 (ARF) from this locus binds mouse double minute 2 (MDM2) and prevents p53 degradation. Loss of ARF, thus leads to a reduction in wild-type p53 levels resulting in a reduced p53 response to DNA damage [7].

Germline TP16 mutations are associated with increased p16/ CDKN2A protein levels that accumulate in senescent oral keratinocytes resulting in keratinocyte immortalisation. Inactivation of p16/CDKN2A can occur by mutation, methylation of promoter sequences or by gene deletion and has been reported in approximately 80% of OSCCs [7].

The results of a study done by Bertonhaa FB et al., suggested that genetic and epigenetic changes involved in loss of function of the PHD (cys 4-his-cys 3 motif in plant homeodomain) finger protein 21B (PHF21B) gene that encodes for PHD finger protein 21B (nuclear protein) of 531 amino acids is observed in OSCC. PHF21B acts as a tumour suppressor as its expression reduces cell migration and colony formation [24].

Polymorphisms of Glutathione-S-Transferese P (GSTP) 1 that encodes a cytoplasmic protein involved in the detoxification of carcinogenic metabolites may be associated with susceptibility to oral cancer [7].

Patients with xeroderma pigmentosum, Fanconi’s anemia and Dyskeratosis Congenita (DC) present with an early onset of OSCC. Two major severe subsets of DC include Hoyeraal-Hreidarsson syndrome and Revesz syndrome [7,25-27].

DC or Zinsser-Engman-Cole syndrome is characterized by mutations in the components of the telomere maintenance machinery resulting in excessively short telomeres especially in highly proliferating tissues [25,26]. These mutations especially DKC1 and TIN 2 results in short telomeres. DKC1 gene encodes a protein Dyskerin which is an essential component of telomerase complex. TINF2 encodes protein TIN2, a component of Shelterin which binds to telomere DNA repeats, protecting them from degradation [26,27].

Through successive generations, the telomeres become critically short and affect the ability of stem cells to continually renew tissues that possess high cellular turn over. Dysfunctional telomeres cause early loss of progenitor cells of rapidly dividing tissues. Loss of dividing progenitor cells starts a vicious cycle by increasing the number of cells recruited into cell cycles. Dysfunctional telomeres activate p53 pathway and increase genomic stability leading eventually to cell crisis, cell cycle arrest, senescence and cell death. Potentially malignant cells develop when rare cells escape cell senescence death and acquire a mechanism to maintain telomere integrity [26].

The other syndromes associated with OSCC include Bloom’s syndrome, Lynch-II syndrome, and Ataxia-telangiectasia [22].

Nasopharyngeal Carcinoma

Familial Nasopharyngeal Carcinoma (NPC) occurs in at least two first degree relatives and has striking ethnic and geographic distribution. It is the leading cause of death in Cantonese and Chinese population. The aetiology of NPC is multifactorial, interaction of race, genetics, environment and Epstein-Barr virus. Reports of genetic clusters suggest a genetic component. Involvement of dietary factors such as consumption of nitrosamine-rich salted fish as seen in South East Asia have one of the highest incidences of NPC [22,28].

NPC is associated with chromosomes 3p21.31-21.2, 4p15.1-q12 and results in poorly differentiated tumours [8].Genetic polymorphisms of some metabolic enzyme genes Cytochrome p450 family 2 sub family E member 1 (CYP2E1) and Glutathione-S-Transferase Mu 1 (GSTM1) and DNA repair genes such as X-ray Repair Cross Complementing 1 (XRCC1) and human Oxoguanineglycosylase 1 (hOGG1) influence susceptibility to NPC. Certain Human Leukocyte Antigen (HLA) groups were also reported to be associated with increased NPC risk [29].

Most patients presents with stage III or IV disease and are aged between 31 to 50 years.

According to a study by Loh KS et al., sex, age and race were similar in familial and non-familial NPC and there were no differences in symptoms between the two groups [30].

Familial Malignant Melanoma

Familial melanoma occurs in the setting of unilateral lineage, with a complex phenotype of early age of onset, multiple atypical moles, multiple primary melanomas, multiple melanomas in the family and in some instances pancreatic cancer [31].

A family history of melanoma is seen in about 10% of cases with an increased risk raise from 4 to >1000 fold; however, individuals with features of true hereditary melanoma are rare. A germline mutation of CDKN2A should be suspected if multiple atypical nevi are found in presence of familial melanomas [31]. CDKN2A chromosomal locus encodes inhibitor p16INK4a (or p16) which is a CDK4/6 inhibitor that induces cellular senescence and helps in DNA repair before mitoses. The p16 regulates intracellular oxidative stress in a cell cycle-independent manner and may also mediate additional functions as it is observed that in vitro, familial melanoma associated p16 mutants still retain CDK4 binding capacity. Incidence of melanoma in p16 mutant relatives is highly associated with chronic exposure to UV radiation due to production of Reactive Oxygen Species (ROS) in the skin. As compared to keratinocytes and fibroblasts, melanocytes are highly susceptible to oxidative stress due to p16 mutation. Hence, it can be concluded that melanocytes are dependent more on p16 for normal oxidative regulation than other cell types which reasons partially on increased incidence of melanoma over other cancers in p16 mutants [32].

Additional mutations seen include CDK4, germline variants in TERT, MITF and BAP1. Melanocytic BAP1-mutation presents with atypical intradermal tumours which should be recognized and treated early [33].

Paraganglioma

The paraganglioma (PG) are defined as neuroendocrine tumours arising from paraganglia and collections of neural crest-derived paraganglionic neuroectodermal cells present throughout the body outside the adrenal system [34,35].

These neoplasms comprise 0.03% of all tumours and 0.6% of all head and neck tumours [34]. Autosomal dominant mode of inheritance with complete penetrance and recently genomic imprinting has been associated with familial PG [36].

In head and neck region, PG arise in 1) carotid body (50%-70%) termed carotid body tumours (CBT) 2) vagus nerve sheath ganglions (5%), 3) chief cells of jugular bulb and 4) along auricular nerve within the tympanic space (20-40%). Head and Neck PG (HNPGLs) are parasympathetically derived and only rarely secrete catecholamines contrasting their sympathetic abdominal counterpart [34].

The syndromes associated with CBTs typically originate in germline mutations of the A, B, C, and D subunits of the mitochondrial complex II enzyme Succinate Dehydrogenase (SDH). SDH catalyses the oxidation of succinate to fumarate in the Krebs cycle and it is involved in the oxidative phosphorylation system where it acts as an electron donor. This mechanism plays a critical role in oxygen sensing and signalling capabilities. Inactivation of SDH due to heterozygous germline mutations would probably mimic a chronic hypoxic stimulation of the chief paraganglionic cells resulting in increased levels of downstream hypoxia effector molecules, leading to cellular proliferation, hyperplasia and ultimately neoplastic transformation of carotid body cells. Genetic markers of hypoxia such as Hypoxia Inducible Factor (HIF)-1 and HIF-2 are upregulated in familial PG syndromes [34].

SDHB carriers (10%-20%) who are young have an increased incidence of head and neck PG malignancy (6-24%, common in carotid body) and abdominal paragangliomas (abPG). It is associated with increased urine metanephrines and plasma catecholamines mainly dopamine levels. Malignant PGs have been known to express biochemically less mature breakdown products [34,35].

SDHD mutations in head and neck PG are identified in 50-94% of cases. They predispose to multifocal PHEOs/PGLs, primarily from the head and neck region, with low metastatic risk [37]. Plasma levels of dopamine and methoxytyramine higher than 0.2 nmol/l constitutes a useful biomarker to detect metastases in such cases [35].

Neurofibromatosis

Neurofibromatosis (NF) is a group of autosomal dominant genetic disorders characterized by multiple cutaneous lesions and tumours of the central and peripheral nervous system. NF is categorized into 2 types NF1 and NF 2 [37].

Neurofibromatosis 1

NF 1 or von Recklinghausen’s disease presents with an incidence of 1 per 2500–3000 individuals and an overall prevalence of 1 in 5000 [38].

NF1 is a familial disorder with a mendelian inheritance pattern, with half of cases caused by newly appearing mutations. It is caused due to a defect in gene located in pericentric region of chromosome 17 on 17q11.2, a multifunctional tumour suppressor gene coding for protein neurofibromin. The development of the disease requires Loss of Heterozygosity (LOH) involving only one cell type in each case that subsequently expands clonally to form a visible lesion. Majority of NF 1 mutations occur due to point changes in the gene coding sequences whereas gene deletion occurs only in a minority of cases. There are mosaic forms in which a late somatic mutation may give rise to mosaic NF. If the mosaicism is limited to one or several body segments it results in segmental or localized NF, whereas early mutations gives rise to conditions clinically indistinguishable from the generalized forms. Type 2 mosacisim is a condition in which a more affected segment is superimposed on generalized disease [39,40].

Loss of function of NF 1 gene results in a RAS opathy. The protein neurofibromin inhibits proliferative growth through blockade of RAS-mediated signal transduction. RAT sarcoma viral oncogene homologue (RAS) is implicated in developmental process such as cell proliferation, differentiation, organogenesis, synaptic plasticity, growth, apoptosis and cell ageing. The protein neurofibromin can also be considered as a modulator of cell motility and cell adhesion. It acts as a negative regulator of rhokinase/rho-associated protein kinase (RHO/ROCK) signalling pathways involved in cytoskeletal dynamics that are instrumental in proper neuronal development [38]. Neurofibromin is expressed in Schwann cells, melanocytes, leukocytes, adrenal glands, neurons and astrocytes of central nervous tissues [40].

Along with criteria put forth by National Institute of Health (NIH), recently, suggestions have been made to add few clinical signs to the diagnostic criteria and include:

  1. Genetic analysis of NF 1 gene.
  2. Cutaneous signs: Nevus Anemicus, juvenile xanthogranuloma, mixed vascular hamartomas, soft-touch skin and hyperpig mentation.
  3. Extracutaneous signs: Astrocytic hamartomas or angiomas; choroidal hamartomas; large head circumference; hypertelorism; unidentified bright objects which are benign progressive lesions in cerebrum; learning, speech and behavioural disabilities; headache and seizures; and neoplasms such as rhabdomyosarcoma, leukaemia, lymphomas, Malignant Peripheral Nerve Sheath Tumours (MPNST), gastrointestinal tumours (4-25%) and pheochromocytomas (0.1% to 5%) [39-41].

The oral manifestations of NF 1 are seen in 72% of cases [37, 38, 42].

Neurofibromatosis 2

A rare disorder with the incidence of 1 in 25,000 to 1 in 40,000 caused due to mutation in NF2 gene located on chromosome 22 (22q12). NF2 gene is a tumour suppressor gene and its product merlin binds to actin or CD44 molecules which are involved with cell interaction with extracellular matrix. The criteria for diagnosis are presented in [Table/Fig-3] [43].

[Table/Fig-3]:
Familial syndromes with oral stigmata.

Neurofibromatosis 3

Previously considered as a subtype of NF2; schwannomatosis or NF 3 is a relatively new condition. It is diagnosed when multiple schwannomas without eighth nerve involvement is noticed. Family history is present in 15-25% of cases. Germline mosaicism of SMARCB1 (INI-1) gene localized on chromosome 22 near NF2 gene is seen. The diagnostic criteria are presented in [Table/Fig-3] [43].

Exclusion Criteria

  1. Germiline pathogenic NF2 mutation.
  2. Fulfilled criteria for NF2.
  3. First degree relative with NF2.
  4. Schwannomas in radiation field only [44].

Familial Oncocytosis

Oncocytes are large epithelial cells with an eosinophilic granular cytoplasm containing many mitochondria (60%) with a swollen appearance. These mitochondria show both structural (globular with lamelliform tubular, or flat cristae) and functional alteration. Familial oncocytic tumours mainly occurs when there is a defect in gene coding mitochondrial respiratory enzymes complex I. Due to this defect, normal aerobic respiration is impaired which results in increased proliferation of mitochondria in the epithelial cells as a compensatory mechanism to supply ATP.

Oncocytomas are of epithelial origin and occur in thyroid, parathyroid, kidney, pituitary gland and salivary glands.

Parotid oncocytomas are associated with Birt-Hogg Dube syndrome (BHD). This syndrome was first described in 1977. The genetic alteration for BHD is mapped to chromosome 17p11.2. This gene codes for folliculin which is a tumour suppressor protein. This protein might also have a role in energy/nutrient sensing signalling pathways which is associated with ATP and mitochondria. The other features of this syndrome include benign proliferations of hair follicle and increased risk for kidney tumours [11,44].

Other Associated Syndromes

The oral manifestations of MEN 2B, HTP-JT, familial OSCC, neuro fibromatoses and the most common familial syndromes with oral stigmata are presented in [Table/Fig-3] [2,7,10,12,14].

Conclusion

Relatives of a person diagnosed with familial tumours should be examined for signs of the syndrome as he or she may be the first person to be affected. The mutations may be present in parents or siblings but they themselves may not be affected and may pass the condition on to their decedents. Depending on the syndrome, genetic professionals can determine who in the family is at risk. Many a times oral manifestations are the first feature, in conditions such as hyperparathyroidism associated ossifying fibroma (30%), leuloplakia with DC (80%), carotid body tumours, neurofibromas, Goltz-Gorlin and Gardner’s syndrome to name a few. Most often dentists are the first to encounter such manifestations and hence, play a major role in identifying the familial cancers.

Acknowledgments

I would like to thank Dr. Sameer Kumar, Post-graduate student, Department of Oral Pathology, Krishnadevaraya College of Dental Sciences, for helping us in the preparation of the manuscript.

Notes

Financial or Other Competing Interests

None.

References

[1] NCI Dictionary of cancer terms [Internet] [Last updated on 2015 April 10; Cited 2017 Feb 16], Last accessed on 2017 May 5]. Available from: http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=256552 .
[2] Marsh DJ, Theodosopoulos G, Howell V, Richardson AL, Benn DE, Proos AL, et al. Rapid mutation scanning of genes associated with familial cancer syndromes using denaturing high-performance liquid chromatography. Neoplasia. 2001;3(3):236–44. [PMC free article] [PubMed]
[3] Longe JL. Gale Encyclopedia of Cancer: A guide to cancer and its treatments. 2nd ed. Vol. 1. Farmington Hills: Thomson Gale; 2005. p. 459.
[4] Neel JV, Schull WJ. Human Heredity. 1st edition. Chicago: University of Chicago Press; 1954.
[5] Kimbrough RD, Mehaffey KR, Grandjean P, Sandoe SH, Rustein DD. A software approach to aetiological diagnosis. 1st ed. New York: Hemisphere Publishing Corporation; 1989. Clinical effects of environmental chemicals.
[6] Wikipedia: free enclyopedia. [Last updated on 2017 April 2; Last cited 2017 April 16, Last accessed on 2017 May 5]. Available from: https://en.wikipedia.org/wiki/Genomic_imprinting .
[7] Prime SS, Thakker NS, Pring M, Guest PG, Paterson IC. A review on inherited cancer syndromes and their relevance to oral squamous cell carcinoma. Oral Oncol. 2001;37(1):01–16. [PubMed]
[8] Schrader KA, Sharaf R, Alanee S, Offit K. Genetic Factors: Hereditary Cancer Predisposition Syndromes [Internet] 2015. [updated 2015 March 4, cited 2016 November 27]. Available from: http://clinicalgate.com/genetic-factors-hereditary-cancer-predispositionsyndromes-16 .
[9] Duan K, Mete O. Familial hyperparathyroidism syndromes. Diagnostic Histopathology. 2016;22(3):92–100.
[10] Suarez C, Rodrigo JP, Ferlito A, Cabanillas R, Shaha AR, Rinaldo A. Tumours of familial origin in the head and neck. Oral Oncol. 2006;42:965–78. [PubMed]
[11] Gasparre G, Romeo G, Rugolo M, Porcelli AM. Learning from oncocytic tumours: Why choose inefficient mitochondria. Biochimica et Biophysica Acta. 2011;1807:633–42. [PubMed]
[12] Ponti G, Tomas A, Manfredin M, Pellacani G. Oral mucosal stigmata in hereditary cancer syndromes: From germline mutations to distinctive clinical phenotypes and tailored therapies. Gene. 2016;582(1):23–32. [PubMed]
[13] Perry A. Familial tumour syndromes. In: Perry A, Brat DJ, editors. Practical Surgical Neuropathology: A Diagnostic Approach. 1st ed. Piladelphia: Churchill Livingstone; 2010. pp. 427–453.
[14] Pan E, Prados MD. Familial Tumours Syndromes of the Central Nervous system. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, editors. Holland-Frei Cancer Medicine. 6th ed. Hamilton: BC Decker Inc; 2003.
[15] Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4) Mol Cell Endocrinol. 2014;386:02–15. [PMC free article] [PubMed]
[16] Spiegel AM. Focus on hereditary endocrine neoplasia. Cancer Cell. 2004;6:327–32. [PubMed]
[17] MacIntosh RB, Shivapuja PK, Krzemien MB, Lee M. Multiple endocrine neoplasia type 2b: maxillofacial significance in 5 cases. J Oral Maxillofac Surg. 2014;72(12):2498. [PubMed]
[18] Winkelmann RK, Carney JA. Cutaneous neuropathology in multiple endocrine neoplasia, type 2b. J Invest Dermatol. 1982;79:307–12. [PubMed]
[19] Usami Y, Takenobu T, Kurihara R, Imai Y, Shinohara S, Fukuda Y, et al. Neural hyperplasia in maxillary bone of multiple endocrine neoplasia type 2B patient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112:783–90. [PubMed]
[20] Chen JD, Morrison C, Zhang C, Kahnoski K, Carpten JD, Teh BT. Hyperparathyroidism-jaw tumour syndrome. Journal of Internal Medicine. 2003;253:634–42. [PubMed]
[21] Yamashita Y, Akiyama T, Mizusawa N, Yoshimoto K, Goto M. A case of hyperparathyroidism jaw tumour syndrome found in the treatment of an ossifying fibroma in the maxillary bone. Int. J. Oral Maxillofac Surg. 2007;36:365–69. [PubMed]
[22] Gnepp DR. Diagnostic surgical pathology of head and neck. 2nd ed. Philadelphia: Saunders, an imprint of Elsevier; 2009.
[23] Manvikar V, Kulkarni R, Koneru A, Vanishree M. Role of human papillomavirus and tumour suppressor genes in oral cancer. J Oral Maxillofac Pathol. 2016;20:106–10. [PMC free article] [PubMed]
[24] Bertonhaa FB, Mateus de Camargo BF, Kuasnea H, Pintor dos Reisb P, Erika da Costa P, Munoza JJAM, et al. PHF21B as a candidate tumour suppressor gene in head and neck squamous cell carcinomas. Molecular Oncology. 2015;9:450–62. [PMC free article] [PubMed]
[25] Noto Z, Tomihara K, Furukawa K, Noguchi M. Dyskeratosis congenital associated with leukoplakia of the tongue. Int J Oral Maxillofac Surg. 2016;45:760–63. [PubMed]
[26] Bessler M, Wilson DB, Mason PJ. Dyskeratosiscongenita. FEBS Lett. 2010;584:3831–38. [PMC free article] [PubMed]
[27] Handley TPB, McCaul JA, Ogden GR. Dyskeratosis congenital. Oral Oncol. 2006;42:331–36. [PubMed]
[28] Wei-Hua J, Bing-Jian F, Zong-Li X, Xiao-Shi Z, Huang P, Li-Xi H, et al. Familial risk and clustering of nasopharyngeal carcinoma in Guangdong, China. Cancer. 2004;101:363–69. [PubMed]
[29] Yang X, Scott Diehl S, Pfeiffer R, Chien-Jen C, Wan-Lun H, Dosemeci M, et al. Evaluation of risk factors for nasopharyngeal carcinoma in high-risk nasopharyngeal carcinoma families in Taiwan. Cancer Epidemiol Biomarkers Prev. 2005;14(4):900–05. [PubMed]
[30] Loh KS, Goh BC, Lu J, Wen-Son H, Tan L. Familial nasopharyngeal carcinoma in a cohort of 200 patients. Arch Otolaryngol Head Neck Surg. 2006;132:82–85. [PubMed]
[31] Soura E, Eliades PJ, Shannon K, Tsao H. Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol. 2016;74(3):395–407. [PMC free article] [PubMed]
[32] Jenkins NC, Jung J, Liu T, Wilde M, Sheri L, Grossman H, et al. Familial melanoma–associated mutations in p16 uncouple its tumour-suppressor functions. J Invest Dermatol. 2013;133:1043–51. [PMC free article] [PubMed]
[33] Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H. Hereditary melanoma: Update on syndromes and management: Emerging melanoma cancer complexes and genetic counselling. J Am Acad Dermatol. 2016;74(3):411–20. [PMC free article] [PubMed]
[34] Collins N, Dietzek A. Contiguous bilateral head and neck paragangliomas in a carrier of the SDHB germline mutation. J Vasc Surg. 2012;55:216–19. [PubMed]
[35] Mediouni A, Ammari S, Wassef M, Gimenez-Roqueploc AP, Laredo JD, Duet M, et al. Malignant head/neck paragangliomas. Comparative Study. Eur Ann Otorhinolaryngol Head Neck Dis. 2014;131:159–66. [PubMed]
[36] Shankavaram U, Fliedner SMJ, Elkahloun AG, Barb JJ, Munson PJ, Thanh T, et al. Genotype and tumour locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas. Neoplasia. 2013;15(4):435–47. [PMC free article] [PubMed]
[37] Javed F, Ramalingam S, Ahmed HB, Gupta B, Sundar C, Qadri T, et al. Oral manifestations in patients with neurofibromatosis type-1: A comprehensive literature review. Crit Rev Oncol Hematol. 2014;91:123–29. [PubMed]
[38] Rad E, Tee AR. Neurofibromatosis type 1: Fundamental insights into cell signalling and cancer. Semin Cell Dev Biol. 2016;52:39–46. [PubMed]
[39] Martin AH, Rodriguez AD. An update on neurofibromatosis type I: not just cafe-aulait spots and freckling. Part II. Other skin manifestations characteristic of NF1.NF 1 and cancer. Actas Dermosifiliogr. 2016;107(6):465–73. [PubMed]
[40] Martin AH, Rodriguez AD. An update on neurofibromatosis type I: not just cafe-aulait spots and neurofibromas. Part I. Dermatological clinical criteria diagnostic of the diseasae. Actas Dermosifiliogr. 2016;107(6):454–64. [PubMed]
[41] Tadini G, Milani D, Menni F, Pezzani L, Sabatini C, Esposito S. Is it time to change the neurofibromatosis 1 diagnostic criteria? Eur J Intern Med. 2014;25:506–10. [PubMed]
[42] Javed F, Ramalingamb S, Ahmed HB, Gupta B, Sundar C, Qadri T, et al. Oral manifestations in patients with neurofibromatosis type-1: A comprehensive literature review. Crit Rev Oncol Hematol. 2014;91:123–29. [PubMed]
[43] Radek M, Tomasik B, Wojdyn M, Snopkowska-Wiaderna D, Błaszczyk M, Radek A. Neurofibromatosis type 2 (NF 2) or schwannomatosis?–Case report study and diagnostic criteria. Neurologia I neurochirurgiapolska. 2016;50:219–25. [PubMed]
[44] Gasparre G, Romeo G, Rugolo M, Porcelli AM. Learning from oncocytic tumours: Why choose inefficient mitochondria? Biochimica et Biophysica Acta. 2011;1807:633–42. [PubMed]

Articles from Journal of Clinical and Diagnostic Research : JCDR are provided here courtesy of JCDR Research & Publications Private Limited